{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:18Z","timestamp":1793121498100,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00314"],"award-info":[{"award-number":["PI21\/00314"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI 19\/01430"],"award-info":[{"award-number":["PI 19\/01430"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00314"],"award-info":[{"award-number":["PI21\/00314"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS cancer foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41375-022-01803-x","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T12:08:56Z","timestamp":1672747736000},"page":"659-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT"],"prefix":"10.1038","volume":"37","author":[{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Poza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Martin-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanira","family":"Ruiz-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-0315","authenticated-orcid":false,"given":"Sara","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Figaredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Rosa-Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Barcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Parrilla","family":"Navamuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-0381","authenticated-orcid":false,"given":"Ricardo","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rufian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"de Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mollejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Felipe","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4863","authenticated-orcid":false,"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycho","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rapado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-9130","authenticated-orcid":false,"given":"Miguel","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Sarandeses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0793-3535","authenticated-orcid":false,"given":"Santiago","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"1803_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9:717\u201320.","journal-title":"Ann Oncol"},{"key":"1803_CR2","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","volume":"131","author":"R K\u00fcppers","year":"2018","unstructured":"K\u00fcppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma. Blood. 2018;131:2297\u2013306.","journal-title":"Blood."},{"key":"1803_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdw026","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016;27:895\u2013901.","journal-title":"Ann Oncol"},{"key":"1803_CR4","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D, Y\u00e1\u00f1ez L, Novelli S, Hern\u00e1ndez-Garcia MT, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23:1631\u201340.","DOI":"10.1016\/j.bbmt.2017.05.021"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/cam4.1217","volume":"6","author":"A Jim\u00e9nez-Ubieto","year":"2017","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D, Y\u00e1\u00f1ez L, Novelli S, Hern\u00e1ndez MT, et al. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Cancer Med. 2017;6:2766\u201374.","journal-title":"Cancer Med"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W, et al. Validation of POD24 as a robust early clinical endpoint of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684\u201393.","journal-title":"Blood"},{"key":"1803_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130\u201340.","journal-title":"Cell Rep"},{"key":"1803_CR8","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575\u201382.","journal-title":"J Clin Oncol"},{"key":"1803_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/hon.2378","volume":"35","author":"M Sorigue","year":"2017","unstructured":"Sorigue M, Mercadal S, Alonso S, Fern\u00e1ndez-\u00c1lvarez R, Garc\u00eda O, Moreno M, et al. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. Hematol Oncol. 2017;35:520\u20137.","journal-title":"Hematol Oncol"},{"key":"1803_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","volume":"178","author":"S Alonso-\u00c1lvarez","year":"2017","unstructured":"Alonso-\u00c1lvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodr\u00edguez G, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699\u2013708.","journal-title":"Br J Haematol"},{"key":"1803_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176\u201381.","journal-title":"Nat Genet"},{"key":"1803_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322.","journal-title":"Lancet Oncol"},{"key":"1803_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112\u201320.","journal-title":"Blood."},{"key":"1803_CR14","doi-asserted-by":"crossref","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618\u201326.","DOI":"10.1200\/JCO.2016.66.9440"},{"key":"1803_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.V128.22.1101.1101","volume":"128","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Versari A, Chartier L, Dupuis J, Tarantino V, Casasnovas R-O, et al. Low suvmax measured on baseline FDG-PET\/CT and elevated \u03b22 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies. Blood. 2016;128:1101\u20131101.","journal-title":"Blood."},{"key":"1803_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132:49\u201358.","journal-title":"Blood."},{"key":"1803_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19:549\u201361.","journal-title":"Lancet Oncol"},{"key":"1803_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood.2019001091","volume":"135","author":"F Mir","year":"2020","unstructured":"Mir F, Barrington SF, Brown H, Nielsen T, Sahin D, Meignan M, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020;135:1214\u20138.","journal-title":"Blood."},{"key":"1803_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/10428194.2020.1821010","volume":"62","author":"P Mozas","year":"2021","unstructured":"Mozas P, Rivero A, Rivas-Delgado A, Nadeu F, Clot G, Correa JG, et al. A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. Leuk Lymphoma. 2021;62:104\u201311.","journal-title":"Leuk Lymphoma"},{"key":"1803_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.21.01234","volume":"40","author":"S Luminari","year":"2022","unstructured":"Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, et al. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40:729\u201339.","journal-title":"J Clin Oncol"},{"key":"1803_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","volume":"2","author":"MH Delfau-Larue","year":"2018","unstructured":"Delfau-Larue MH, Van Der Gucht A, Dupuis J, Jais JP, Nel I, Beldi-Ferchiou A, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: Distinct prognostic value in follicular lymphoma. Blood Adv. 2018;2:807\u201316.","journal-title":"Blood Adv"},{"key":"1803_CR22","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.18632\/oncotarget.14448","volume":"8","author":"C Sarkozy","year":"2017","unstructured":"Sarkozy C, Huet S, Carlton VEH, Fabiani B, Delmer A, Jardin F, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8:8765\u201374.","journal-title":"Oncotarget."},{"key":"1803_CR23","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679\u201387.","journal-title":"Blood."},{"key":"1803_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537\u201347.","journal-title":"Nat Biotechnol."},{"key":"1803_CR25","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","volume":"19","author":"J Trotman","year":"2018","unstructured":"Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19:1530\u201342.","journal-title":"Lancet Oncol"},{"key":"1803_CR26","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30:4317\u201322.","journal-title":"J Clin Oncol"},{"key":"1803_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/annonc\/mdn629","volume":"20","author":"HS Han","year":"2009","unstructured":"Han HS, Escal\u00f3n MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin\u2019s lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20:309\u201318.","journal-title":"Ann Oncol"},{"key":"1803_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.mayocp.2012.03.006","volume":"87","author":"SM Ansell","year":"2012","unstructured":"Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: Convention and controversy. Mayo Clin Proc. 2012;87:571\u201380.","journal-title":"Mayo Clin Proc"},{"key":"1803_CR29","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","volume":"101","author":"S Luminari","year":"2016","unstructured":"Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, et al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the fondazione italiana linfomi. Haematol Ferrata Storti Found. 2016;101:e66\u20138.","journal-title":"Haematol Ferrata Storti Found"},{"key":"1803_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"1803_CR31","doi-asserted-by":"publisher","first-page":"e154941","DOI":"10.1172\/JCI154941","volume":"132","author":"DK Dang","year":"2022","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Investig. 2022;132:e154941.","journal-title":"J Clin Investig"},{"key":"1803_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3324\/haematol.2018.194712","volume":"104","author":"E Onecha","year":"2019","unstructured":"Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, et al. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2019;104:288.","journal-title":"Haematologica."},{"key":"1803_CR33","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez R, Dorado S, Ru\u00edz-Heredia Y, Mart\u00edn-Mu\u00f1oz A, Rosa-Rosa JM, Ribera J, et al. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Sci Rep. 2022;12:13057.","DOI":"10.1038\/s41598-022-17271-3"},{"key":"1803_CR34","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","volume":"123","author":"A Bouska","year":"2014","unstructured":"Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 2014;123:1681\u201390.","journal-title":"Blood."},{"key":"1803_CR35","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","volume":"20","author":"S Galimberti","year":"2014","unstructured":"Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398\u2013405.","journal-title":"Clin Cancer Res"},{"key":"1803_CR36","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845\u201353.","journal-title":"J Clin Oncol"},{"key":"1803_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541\u20139.","journal-title":"Lancet Oncol"},{"key":"1803_CR38","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131:2413\u201325.","journal-title":"Blood"},{"key":"1803_CR39","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201367.","journal-title":"J Clin Oncol"},{"key":"1803_CR40","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30:4317\u201322.","journal-title":"J Clin Oncol"},{"key":"1803_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.mayocp.2012.03.006","volume":"87","author":"SM Ansell","year":"2012","unstructured":"Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc. 2012;87:571\u201380.","journal-title":"Mayo Clin Proc"},{"key":"1803_CR42","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","volume":"126","author":"F Zohren","year":"2015","unstructured":"Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126:1407\u201314.","journal-title":"Blood."},{"key":"1803_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","volume":"128","author":"C Pott","year":"2016","unstructured":"Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613\u2013613.","journal-title":"Blood."},{"key":"1803_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","volume":"356","author":"S Siva","year":"2015","unstructured":"Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356:82\u201390.","journal-title":"Cancer Lett"},{"key":"1803_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","volume":"3","author":"M Roschewski","year":"2022","unstructured":"Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood cancer Discov. 2022;3:5\u201315.","journal-title":"Blood cancer Discov"},{"key":"1803_CR46","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.","journal-title":"Sci Transl Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01803-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T04:30:29Z","timestamp":1678163429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01803-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1914377\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RA, JML, and SB are equity shareholders of Altum Sequencing Co. LLFC received honoraria and received research funding from Roche, Novartis, Astra Zeneca, Janssen, B.M.S., Pfizer and Incyte. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}